US WorldMeds Acquires Adaptimmune’s Cell Therapy Assets
August 5, 2025
US WorldMeds reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc’s (Adaptimmune) cell–therapy assets—including TECELRA® (afamitresgene autoleucel), lete–cel, afami–cel, and uza–cel. The acquisition